Cite
HARVARD Citation
Choi, J. et al. (2020). Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer. Medicine. 99 (46), p. . [Online].